GlassScriptPhysician profile
Candace S Day
NPI 1285190470
$2,365.19
in general payments reported to CMS, 2019-2025
27 companies · $573 in 2025
The $573 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $527 · 2022: $437 · 2023: $391 · 2024: $437 · 2025: $573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,401.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,401.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $342.37 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $268.24 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $225.31 | 2021-2022 | |
| Lilly USA, LLC | $218.50 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $191.13 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $151.13 | 2021-2025 | |
| Novo Nordisk INC | $135.98 | 2021-2025 | Rybelsus, Ozempic |
| Astellas Pharma US INC | $86.92 | 2023-2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $85.22 | 2023-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $83.11 | 2021-2023 | Trintellix |
| Amgen INC. | $78.02 | 2024-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $66.97 | 2021-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Glaxosmithkline, LLC. | $58.32 | 2021-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Exact Sciences Corporation | $56.37 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Scilex Pharmaceuticals INC. | $37.86 | 2023 | Ztlido |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $36.05 | 2023 | Quviviq |
| Nevro Corp. | $34.09 | 2022 | |
| Inspire Medical Systems, INC. | $31.70 | 2025 | Inspire |
| Dexcom, INC. | $25.31 | 2024 | Dexcom G6 Transmitter |
| Eisai INC. | $22.68 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.75 | 2022 | |
| Nestle Healthcare Nutrition INC. | $21.11 | 2021 | |
| Vbi Vaccine (Delaware) INC. | $19.38 | 2022 | |
| Circassia INC. | $18.17 | 2025 | Niox |
| Optos, INC. | $17.61 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.16 | 2023 | Cycloset |
| Phadia US INC. | $15.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Candace Day listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.